Advertisement

Topics

Immunomic Therapeutics, Inc.(ITI) Company Profile

19:12 EDT 21st October 2018 | BioPortfolio

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax for use in the prevention and treatment of allergic diseases which resulted in over $350M in licensing revenue that year, the company has now focused on the application of LAMP technology in oncology. For information about ITI and LAMP Technology, visit www.immunomix.com.


News Articles [780 Associated News Articles listed on BioPortfolio]

Immunomic Therapeutics to Present at the 2018 BIO Investor Forum

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 2018 BIO Investor Forum being held...

Immunomic Therapeutics CEO to Present at Precision Medicine World Conference (PMWC): Emerging Therapeutics Showcase

Presentation to Highlight UNITE Potential Capabilities in Immuno-Oncology Tomorrow, Dr. William Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, I...

Tomorrow: Immunomic Therapeutics CEO at Outsourcing in Clinical Trials Mid-Atlantic

ITI Founder & CEO will discuss new developments in cancer immunotherapy Tomorrow, Bill Hearl, Ph.D., Founder and Chief Executive Officer (CEO) of Immunomic Therapeu...

Immunomic Therapeutics Senior Vice President of R&D to Participate in Bio+Tech Conference

Sr. VP of R&D will discuss lysosomal targeting technology as applied in cancer immunotherapy Tomorrow, Teri Heiland, Ph.D., Senior Vice President of Research and De...

Immunomic Therapeutics CEO to Present at Immuno-Oncology Summit

Presentation to Highlight the Challenges of Viral Targets in Cancer Tomorrow, Dr. Bill Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, Inc. will present...

Immunomic CEO to Speak at 2018 BioHealth Capital Region Forum

Panel Will Discuss Strengths in BioHealth Immunotherapies Immunomic Therapeutics, Inc. (ITI) CEO Bill Hearl, Ph.D., will participate in a panel discussion on immunotherapy at ...

Immunomic Therapeutics CEO to Join Panel at 18th Annual Biotech in Europe Forum

Panel to Highlight Advanced Therapeutics for Oncology Tomorrow, William Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, Inc., will participate in a pane...

Immunomic Therapeutics to Present at the 2018 China BioMed Innovation and Investment Conference

Presentation to Highlight UNITE technology application to oncology Today, Sia Anagnostou, Head, China Corporate Development of Immunomic Therapeutics, Inc. (ITI) and Senior Sc...

PubMed Articles [446 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Clinical Trials [158 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1263 Associated Companies listed on BioPortfolio]

Immunomic Therapeutics, Inc.(ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These inve...

Immunomic Therapeutics (ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These i...

Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing ne...

Immunomic Therapeutics, Inc. (ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing ne...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Immunomic Therapeutics, Inc.(ITI)" on BioPortfolio

We have published hundreds of Immunomic Therapeutics, Inc.(ITI) news stories on BioPortfolio along with dozens of Immunomic Therapeutics, Inc.(ITI) Clinical Trials and PubMed Articles about Immunomic Therapeutics, Inc.(ITI) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomic Therapeutics, Inc.(ITI) Companies in our database. You can also find out about relevant Immunomic Therapeutics, Inc.(ITI) Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...


Corporate Database Quicklinks



Searches Linking to this Company Record